Among the putative candidates for targeted therapies in HCC is the c-Myc protooncogene, which is frequently over-expressed and/or amplified in HCC and whose levels directly correlate with the poor outcome of HCC patients [4-8]. This evidence concerns the gene MYC and hepatocellular carcinoma.